Long-Term Call Buying Activity in Twitter (TWTR) Targets Upside in Shares Above $70 -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Summit Insights Downgrades Twitter, Inc. (TWTR) to Hold
February 8, 2019 10:29 AM ESTSummit Insights downgraded Twitter, Inc. (NYSE: TWTR) from Buy to Hold.
For an analyst ratings summary and ratings history on Twitter, Inc. click here. For more ratings news on Twitter, Inc. click here.
Shares of Twitter, Inc. closed at $30.80 yesterday.
... MoreTwitter, Inc. (TWTR) PT Lowered to $33 at Oppenheimer
February 8, 2019 9:25 AM ESTOppenheimer analyst Jason Helfstein lowered the price target on Twitter, Inc. (NYSE: TWTR) to $33.00 (from $37.00) while maintaining a Outperform rating.
The analyst commented, "We are lowering our target to $33 from $37 on reduced estimates, but maintaining our Outperform rating as we believe the... More
Twitter, Inc. (TWTR) PT Lowered to $33 at Susquehanna
February 8, 2019 9:01 AM ESTSusquehanna analyst Shyam Patil lowered the price target on Twitter, Inc. (NYSE: TWTR) to $33.00 (from $35.00) while maintaining a Neutral rating.
"Higher spending surprises but fundamentals actually looking ok," the analyst commented.
... MoreTwitter, Inc. (TWTR) PT Lowered to $33 at Baird
February 8, 2019 8:37 AM ESTBaird analyst Colin Sebastian lowered the price target on Twitter, Inc. (NYSE: TWTR) to $33.00 (from $35.00) while maintaining a Neutral rating.
... MoreTwitter, Inc. (TWTR) PT Lowered to $38 at UBS
February 8, 2019 7:58 AM ESTUBS analyst Eric Sheridan lowered the price target on Twitter, Inc. (NYSE: TWTR) to $38.00 (from $40.00) while maintaining a Buy rating.
... MoreTwitter, Inc. (TWTR) PT Lowered to $31 at Morgan Stanley
February 8, 2019 7:37 AM ESTMorgan Stanley lowered its price target on Twitter, Inc. (NYSE: TWTR) to $31.00 (from $33.00) while maintaining a Equalweight rating.
... MoreTwitter (TWTR) Gross Margins Likely To Remain Elevated, Reit Neutral At Nomura
February 8, 2019 6:46 AM ESTNomura/Instinet analyst, Mark Kelley, reiterated his Neutral rating on shares of Twitter, Inc. (NYSE: TWTR) after the company reported 4Q18 results above consensus, but Opex guidance for 2019 indicates a significant step up vs. expectations. Total monetizable DAUs grew 9% YoY to 126mn (US +5% YoY to 27mn;... More
Twitter, Inc. (TWTR) PT Lowered to $28 at Deutsche Bank
February 8, 2019 5:40 AM ESTDeutsche Bank analyst Lloyd Walmsley lowered the price target on Twitter, Inc. (NYSE: TWTR) to $28.00 (from $30.00) while maintaining a Hold rating.
... MorePre-Open Stock Movers 02/07: (IRBT) (LCI) (STI) Higher; (SLDB) (OSUR) (GRUB) Lower (more...)
February 7, 2019 9:27 AM ESTToday's Pre-Open Movers
Solid Biosciences (Nasdaq: SLDB) 72.8% LOWER; announced today preliminary findings from IGNITE DMD, the Companys Phase I/II dose-ascending clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD). Initial three-month biopsy data showed low levels of microdystrophin protein expression. The Company is currently engaging with the appropriate parties to dose escalate as planned and as soon as possible.
Twitter (TWTR) Tops Q4 EPS by 6c, Revenue Beats, Offers Guidance
February 7, 2019 7:03 AM ESTTwitter (NYSE: TWTR) reported Q4 EPS of $0.31, $0.06 better than the analyst estimate of $0.25. Revenue for the quarter came in at $908.8 million versus the consensus estimate of $869.5 million.
Average monetizable daily active users (mDAU) were 126 million for Q4, compared to 115 million in the same period of the previous year and compared to 124 million in the previous quarter.Average US mDAU were 27 million for Q4,... More
